Jun 10, 2026
HeartSciences opens AI marketplace for heart care
The company’s latest platform update brings FDA-cleared heart AI into everyday care and expands its recurring revenue strategy.
Investors have poured billions into artificial intelligence being integrated with healthcare. Researchers have published promising results. Startups have raced to develop algorithms that can detect disease earlier and more accurately. Yet one question remains: once an AI tool is built for healthcare, how does it actually reach patients?
That challenge is being addressed by a new announcement from AI-driven medtech company HeartSciences. It has launched version 1.3 of its MyoVista Insights platform, introducing an AI-ECG Algorithm Marketplace that allows healthcare providers to access FDA-cleared cardiac AI tools through a single system [1].
The first entrant is an FDA-cleared algorithm from Bunkerhill Health that can help clinicians identify signs of reduced heart pumping function using a routine electrocardiogram (ECG) – one of the most widely used diagnostic tests in medicine.
An app store for cardiac AI? The modern smartphone became far more valuable when it evolved from a device into a platform. Once developers could build apps that lived within a common ecosystem, innovation accelerated. HeartSciences appears to be betting on a similar idea.
Rather than focusing solely on developing its own algorithms, the company is creating a marketplace where multiple AI developers can potentially distribute their products through a single clinical platform.
For hospitals and physician practices, that could simplify adoption. Instead of integrating numerous AI solutions separately, clinicians could access multiple tools through one workflow.
For developers, it may remove a significant obstacle. Creating an algorithm is only half the battle. Getting it embedded into clinical workflows, connected to electronic health records and used consistently by healthcare professionals is often the harder part. Many promising technologies never make it beyond pilot projects because deployment proves more difficult than development.
“The launch of our AI-ECG marketplace is a defining milestone for HeartSciences,” said Andrew Simpson, CEO of HeartSciences. “We are now delivering a cleared AI-ECG algorithm into clinical workflows through MyoVista Insights, with a recurring, SaaS-based revenue model that we believe can create meaningful and scalable value for the Company.”
The marketplace’s first FDA-cleared algorithm focuses on a condition that often flies under the radar until symptoms become difficult to ignore. The technology analyzes data from a standard 12-lead ECG and helps identify patients who may have reduced left ventricular ejection fraction, essentially a measure of how effectively the heart is pumping blood around the body.
In heart failure, patients may have no obvious symptoms while underlying changes are already taking place. By extracting additional insights from a routine ECG, clinicians may be able to identify patients who warrant further evaluation sooner rather than later.
Importantly, the technology does not replace physicians or make diagnoses on its own. Instead, it acts as an additional layer of intelligence applied to a test that is already performed millions of times each year.
From an investment perspective, the launch highlights how the value of AI increasingly depends not only on how accurate an algorithm is, but on whether healthcare systems can actually use it at scale.
HeartSciences’ marketplace is designed around a software-as-a-service (SaaS) model, generating recurring revenue as institutions use the platform and access AI-powered assessments. The company is already in discussions with additional developers and expects to add more third-party algorithms over time. That strategy could prove significant in a market where many AI companies are competing for attention, but relatively few have established clear pathways to commercialization.
According to Simpson, Bunkerhill’s ECG-EF algorithm represents just the beginning of a larger trend, as they are currently in active discussions with other algorithm developers. He emphasized that these developers increasingly understand that the true challenge and critical milestone lies in successfully integrating these algorithms into actual clinical practice, rather than merely creating them.
Moreover, much of modern medicine still operates after disease becomes visible. Longevity science, by contrast, is increasingly focused on identifying risk earlier, before symptoms emerge and before damage becomes harder to reverse. AI-enhanced diagnostics fit naturally into that vision.
The most powerful longevity technologies, in many cases, could be tools that extract more meaningful information from procedures already sitting inside routine healthcare. An ECG is hardly cutting-edge technology; it has been around for more than a century. What is changing is our ability to uncover signals hidden within the data it generates.
“We share HeartSciences’ commitment to making advanced cardiac AI more accessible in everyday clinical practice,” said Nishith Khandwala, Co-founder and CEO of Bunkerhill Health. “This collaboration gives more health systems a pathway to adopt our FDA-cleared ECG-EF algorithm and to use routine ECG data to support earlier evaluation and more informed clinical decisions for patients at risk of heart failure.”
That may ultimately be the most important takeaway from this launch. Preventive healthcare is building the infrastructure that allows algorithms to become part of everyday medicine. HeartSciences is putting it out there that the next phase of healthcare AI will be defined by distribution, not just invention alone.